Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

Zeissig, Sebastian, Rosati, Elisa, Dowds, C Marie, Aden, Konrad, Bethge, Johannes, Schulte, Berenice, Pan, Wei Hung, Mishra, Neha, Zuhayra, Maaz, Marx, Marlies, Paulsen, Maren, Strigli, Anne, Conrad, Claudio, Schuldt, Dörthe, Sinha, Anupam, Ebsen, Henriette, Kornell, Sabin-Christin, Nikolaus, Susanna, Arlt, Alexander, Kabelitz, Dieter, Ellrichmann, Mark, Lützen, Ulf, Rosenstiel, Philip C, Franke, Andre, Schreiber, Stefan · 2019 · Gut

Abstract

Objective: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn’s disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore performed a comprehensive analysis of vedolizumab-induced alterations in mucosal and systemic immunity in patients with inflammatory bowel disease (IBD), using anti-inflammatory therapy with the TNFα antibody infliximab as control. Design: Immunophenotyping, immunohistochemistry, T cell receptor profiling and RNA sequencing were performed using blood and colonic biopsies from patients with IBD before and during treatment with vedolizumab (n=18) or, as control, the anti-TNFα antibody infliximab (n=20). Leucocyte trafficking in vivo was assessed using single photon emission computed tomography and endomicroscopy. Results: Vedolizumab was not associated with alterations in the abundance or phenotype of lamina propria T cells and did not affect the mucosal T cell repertoire or leucocyte trafficking in vivo. Surprisingly, however, α4β7 antibody treatment was associated with substantial effects on innate immunity including changes in macrophage populations and pronounced alterations in the expression of molecules involved in microbial sensing, chemoattraction and regulation of the innate effector response. These effects were specific to vedolizumab, not observed in response to the TNFα antibody infliximab, and associated with inhibition of intestinal inflammation. Conclusion: Our findings suggest that modulation of innate immunity contributes to the therapeutic efficacy of vedolizumab in IBD. Trial registration number: NCT02694588

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-316023

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 203

Metadata

Authors
Zeissig, S., Rosati, E., Dowds, C. M., Aden, K., Bethge, J., Schulte, B., Pan, W. H., Mishra, N., Zuhayra, M., Marx, M., Paulsen, M., Strigli, A., Conrad, C., Schuldt, D., Sinha, A., Ebsen, H., Kornell, S.-C., Nikolaus, S., Arlt, A., Kabelitz, D., Ellrichmann, M., Lützen, U., Rosenstiel, P. C., Franke, A., & Schreiber, S.
Venue
Gut
Publisher
BMJ
Published
2018-05-05
Volume
68
Issue
1
Pages
25-39
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2801753207
Cited by
203
References
5
FWCI
13.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.1136/gutjnl-2018-316023
The paper
Zeissig, S., Rosati, E., Dowds, C. M., Aden, K., Bethge, J., Schulte, B., Pan, W. H., Mishra, N., Zuhayra, M., Marx, M., Paulsen, M., Strigli, A., Conrad, C., Schuldt, D., Sinha, A., Ebsen, H., Kornell, S.-C., Nikolaus, S., Arlt, A., . . . Schreiber, S. (2019). Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. https://doi.org/10.1136/gutjnl-2018-316023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.